슈퍼너스 파마슈티컬스(Supernus Pharmaceuticals, Inc.)
US ˙ NasdaqGM ˙ US8684591089

SecuritySUPN / Supernus Pharmaceuticals, Inc.
InstitutionUBS Group AG
Latest Disclosed Ownership209,124 shares
Latest Disclosed Value $ 10,809,619
UBS Group AG ownership in SUPN / Supernus Pharmaceuticals, Inc.

On May 5, 2026 - UBS Group AG filed a 13F-HR form disclosing ownership of 209,124 shares of Supernus Pharmaceuticals, Inc. (US:SUPN) valued at $10,809,620 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 29, 2026 disclosing 43,047 shares of Supernus Pharmaceuticals, Inc.. This represents a change in shares of 385.80% during the quarter. The current value of the position is $9,347,843 USD.

UBS Group AG has a history of taking positions in derivatives of the underlying security (SUPN) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

SUPN / Supernus Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-05 2026-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 209,124 166,077 385.80 10,810 405.33 0.0003
2026-01-29 2025-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 43,047 -497,076 -92.03 2,139 -91.71 0.0003
2025-11-13 2025-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 540,123 312,775 137.58 25,812 260.20 0.0040
2025-08-14 2025-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 227,348 -22,968 -9.18 7,166 -12.58 0.0012
2025-05-13 2025-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 250,316 50,290 25.14 8,198 13.34 0.0015
2025-02-14 2024-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 200,026 91,168 83.75 7,233 113.08 0.0013
2024-11-14 2024-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 108,858 28,772 35.93 3,394 58.45 0.0007
2024-08-14 2024-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 80,086 15,542 24.08 2,142 -2.68 0.0005
2024-05-13 2024-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 64,544 -875 -1.34 2,202 16.27 0.0005
2024-02-09 2023-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 65,419 46,390 243.79 1,893 261.26 0.0006
2023-11-09 2023-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 19,029 -34,884 -64.70 525 -67.65 0.0002
2023-08-11 2023-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 53,913 14,278 36.02 1,621 12.89 0.0005
2023-05-12 2023-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 39,635 11,573 41.24 1,436 43.50 0.0005
2023-02-08 2022-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 28,062 20,517 271.93 1,001 290.63 0.0004
2022-11-10 2022-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 7,545 5,961 376.33 256 468.89 0.0001
2022-08-10 2022-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 1,584 -82,180 -98.11 45 -98.34 0.0000
2022-05-16 2022-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 83,764 -15,235 -15.39 2,707 -6.20 0.0009
2022-02-14 2021-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 98,999 95,951 3,148.00 2,886 3,462.96 0.0008
2021-11-15 2021-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 3,048 -21,095 -87.38 81 -89.11 0.0000
2021-08-13 2021-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 24,143 -151,006 -86.22 744 -83.77 0.0002
2021-05-12 2021-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 175,149 -6,233 -3.44 4,585 0.46 0.0015
2021-02-11 2020-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 181,382 164,612 981.59 4,564 1,204.00 0.0015
2020-11-12 2020-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 16,770 -12,947 -43.57 350 -50.42 0.0001
2020-07-31 2020-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 29,717 -11,111 -27.21 706 -3.81 0.0003
2020-05-01 2020-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 40,828 -12,747 -23.79 734 -42.25 0.0003
2020-02-14 2019-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 53,575 -33,551 -38.51 1,271 -71.66 0.0004
2019-11-14 2019-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 87,126 -609,136 -87.49 4,485 -80.53 0.0017
2019-08-14 2019-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 696,262 19,911 2.94 23,040 -2.78 0.0089
2019-05-14 2019-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 676,351 325,468 92.76 23,699 103.32 0.0098
2019-02-14 2018-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 350,883 28,143 8.72 11,656 -28.27 0.0053
2018-11-14 2018-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 322,740 293,120 989.60 16,250 816.53 0.0064
2018-08-14 2018-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 29,620 15,274 106.47 1,773 169.86 0.0008
2018-05-15 2018-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 14,346 641 4.68 657 20.33 0.0003
2018-02-14 2017-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 13,705 -30,817 -69.22 546 -69.34 0.0002
2017-11-14 2017-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 44,522 29,740 201.19 1,781 179.59 0.0008
2017-11-14 2017-06-30 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 14,782 -158 -1.06 637 36.11 0.0003
2017-08-14 2017-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 14,782 -158 637
2017-11-14 2017-03-31 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 14,940 -5,071 -25.34 468 -7.33 0.0003
2017-05-12 2017-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 14,940 -5,071 468
2017-02-14 2016-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 20,011 -7,678 -27.73 505 -26.17 0.0003
2016-11-14 2016-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 27,689 23,175 513.40 684 643.48 0.0004
2016-08-12 2016-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 4,514 32 0.71 92 35.29 0.0001
2016-05-12 2016-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 4,482 -47,448 -91.37 68 -90.26 0.0000
2016-02-16 2015-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 51,930 1,701 3.39 698 -0.99 0.0005
2015-11-13 2015-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 50,229 3,212 6.83 705 -11.65 0.0005
2015-08-14 2015-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 47,017 2,393 5.36 798 47.78 0.0005
2015-05-14 2015-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 44,624 12,283 37.98 540 100.74 0.0004
2015-02-17 2014-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 32,341 32,341 269 0.0002
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2015-05-14 2015-03-31 13F SUPERNUS PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2015-02-17 2014-12-31 13F SUPERNUS PHARMACEUTICALS COM Call 800 7 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2017-11-14 2017-09-30 13F SUPERNUS PHARMACEUTICALS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2017-11-14 2017-06-30 13F/A SUPERNUS PHARMACEUTICALS COM Put 45,800 0.00 1,974 37.66 n/a n/a n/a
2017-08-14 2017-06-30 13F SUPERNUS PHARMACEUTICALS COM Put 45,800 1,974 n/a n/a n/a
2017-11-14 2017-03-31 13F/A SUPERNUS PHARMACEUTICALS COM Put 45,800 1,434 n/a n/a n/a
2017-05-12 2017-03-31 13F SUPERNUS PHARMACEUTICALS COM Put 45,800 1,434 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.